Which Digital CBT-I Insomnia Apps Are Now Reimbursed by European Health Insurers

Digital CBT-I Reimbursement in Europe: What "Covered" Actually Means

Digital CBT-I reimbursement in Europe now depends almost entirely on which country issues your health insurance card. Cognitive behavioral therapy for insomnia (CBT-I) delivered through an app is the first-line treatment recommended by European sleep societies, but whether an insurer pays for it varies from full reimbursement to zero coverage within a single continent. Germany pays for two named apps outright. The UK offers one free through parts of the NHS. France has no standard pathway at all. Patients often discover this only after a GP or an online sleep clinic consultation has already recommended a CBT-I app, then hit a paywall their insurer never mentioned.

This guide breaks down exactly which programmes are reimbursed, in which country, at what price, and under what conditions, as of 2026. It also flags a gap that reimbursement guides rarely mention: insomnia and undiagnosed sleep apnea overlap often enough that a CBT-I app alone will not solve every case.

Chronic insomnia affects roughly 10% of European adults on average, though country-level rates range from 5.8% to 34.8% depending on how it is measured, according to a 2023 epidemiological review from the European Sleep Research Society and European Insomnia Network published in PMC. Left untreated, insomnia, sleep apnea, and restless legs syndrome together cost the European economy an estimated €158 billion a year, split roughly evenly between direct medical spending and indirect costs like lost productivity, according to 2026 research published in the European Journal of Neurology. That economic weight is exactly why several health systems are now willing to pay for an app instead of a therapist's couch.

Germany: The Only Country With Full Digital CBT-I Reimbursement

Germany is the only European country where digital CBT-I reimbursement is automatic, full, and available nationwide. It runs through the DiGA scheme (Digitale Gesundheitsanwendungen), a government-approved list of digital health apps that any statutory health insurer (Krankenkasse) must pay for once a physician or psychotherapist writes a prescription or a patient requests one directly using a diagnosis code.

Two insomnia-specific apps currently sit on that list. Somnio is reimbursed at a fixed price of €224.99 for a 90-day prescription period, and Somnovia at €236 for the same 90 days, according to listings in the BfArM DiGA-Verzeichnis (2025-2026). Patients pay nothing out of pocket beyond the standard statutory co-payment rules that apply to most prescriptions, and no prior authorization battle is required the way it often is for durable medical equipment. As of March 2025, 59 digital health apps in total were listed as reimbursable across all conditions in Germany's directory, according to Med Tech Reimbursement Consulting, with insomnia being one of the more mature categories.

The rules are changing again in 2026. Germany's DiGA framework is shifting to outcomes-based pricing, called AbEM, which ties at least 20% of an app's reimbursed price to measured patient outcomes rather than a flat negotiated rate. Manufacturers must now report continuous outcomes data to BfArM to keep their listing and pricing intact, according to DiGA pathway analyses from Med Tech Reimbursement Consulting. In practice this means prices for Somnio and Somnovia could shift through 2026 as performance data comes in, though the reimbursement mechanism itself remains in place. For the wider rules on how German statutory insurers handle sleep disorders generally, including apnea diagnostics and devices, see our step-by-step guide to Krankenkasse coverage for sleep apnea treatment.

United Kingdom: Free Through the NHS, But Not Everywhere

The UK reimburses digital CBT-I through a national cost-effectiveness recommendation rather than a fixed pricing directory. In May 2022, the National Institute for Health and Care Excellence (NICE) issued Medical Technologies Guidance MTG70, recommending Sleepio as cost-saving compared with usual primary care, at a supplier price of £45 per patient. That recommendation was based on 12 randomized controlled trials showing the app outperformed standard sleep hygiene advice and reduced reliance on sleeping-pill prescribing.

The catch is that a NICE recommendation is not a national reimbursement mandate the way DiGA is in Germany. Coverage still runs through individual NHS boards and Integrated Care Boards (ICBs), which decide locally whether to commission the app. Sleepio is free at the point of use nationwide in NHS Scotland and through a number of English ICBs, typically accessed via GP referral or an IAPT (talking therapies) service. In areas that have not commissioned it, patients are left to pay privately or wait for a face-to-face CBT-I referral, which can carry a long waiting list.

This patchwork mirrors a broader pattern in UK sleep care: diagnosis and referral pathways for both insomnia and sleep apnea increasingly route through remote consultations rather than in-person clinics, a shift covered in detail in our overview of telemedicine-based sleep clinics operating across Europe.

France: No Standard Reimbursement Yet, Only a Capped Workaround

France does not yet reimburse any digital CBT-I app through its standard health insurance track. No insomnia app has cleared what French regulators call "remboursement de droit commun," the ordinary path to inclusion on the list of insurer-reimbursed treatments that applies to most approved medical products.

The one workaround currently available is an accelerated early-access mechanism known as PECAN (forfait innovation numérique), a temporary digital-innovation funding track that lets French regulators reimburse a promising digital therapeutic before it completes the full standard process. Under the decree of 22 April 2024 that sets PECAN's payment rules, Assurance Maladie pays an initial flat fee of €435 for the first three months, then €38.30 per month, up to a ceiling of €780 per patient per year, according to France's national digital-health agency (Agence du Numérique en Santé) and Assurance Maladie. Access is decided case by case rather than granted automatically the way a DiGA prescription is in Germany. Outside of that narrow route, French patients currently pay the full cash price for any CBT-I app themselves, or rely on employer or supplemental mutuelle coverage if their private plan happens to include digital therapeutics.

Italy, Spain, the Netherlands and Belgium: Paying Out of Pocket for Now

Most of the rest of Europe has no national digital CBT-I reimbursement scheme at all. Italy, Spain, the Netherlands, and Belgium have no equivalent of Germany's DiGA directory or the UK's NICE technology appraisal process for insomnia apps specifically. Patients in these markets generally fall into one of three groups: paying the app's list price directly, accessing it through a private health insurance add-on or employer wellness benefit, or being referred to traditional face-to-face CBT-I through a public mental health service, which typically carries longer waits than an app-based programme.

This is not necessarily permanent. Several of these countries have digital-health reimbursement frameworks in earlier stages of development for other app categories, and insomnia-specific listings could follow Germany's model in coming years. For now, though, a patient in Amsterdam, Milan, Barcelona, or Brussels searching for a reimbursed CBT-I app will not currently find one through their national insurer.

Digital CBT-I Reimbursement in Europe Compared Country by Country

The table below summarizes digital CBT-I reimbursement status across the markets covered above, current as of 2026.

How to Find Out If Your CBT-I App Is Reimbursed

Checking eligibility takes a few concrete steps rather than guesswork, and the process differs by country.

When Insomnia Is Actually a Breathing Problem

Chronic difficulty sleeping is not always a cognitive or behavioral issue that CBT-I alone can resolve. Insomnia symptoms and undiagnosed sleep apnea are linked closely enough that a meaningful share of patients prescribed a DiGA or NHS CBT-I programme for "trouble sleeping" are never screened for sleep-disordered breathing first. CBT-I retrains thoughts and habits around sleep; it does not open a physically obstructed airway.

Simple screening tools already exist for this, including the Epworth Sleepiness Scale and the Berlin Questionnaire, both commonly used in primary care to flag patients who may need a sleep apnea work-up before or alongside starting a CBT-I programme. If you snore loudly, wake up gasping or choking, have been told by a partner that you stop breathing during sleep, or score positively on one of these screens, it is worth requesting an apnea assessment rather than assuming an insomnia app will fix the underlying cause.

For patients confirmed to have primary snoring or mild-to-moderate obstructive sleep apnea rather than, or alongside, insomnia, a soft silicone intranasal stent such as Back2Sleep offers a non-drug, non-CBT option that works differently: it is a CE-certified Class I device that keeps the nasal airway open overnight, requires no prescription, and comes as a starter kit with four sizes to find the right fit. It is not a treatment for insomnia and does not replace CBT-I, but it can complement sleep hygiene work on the airway side of the problem once sleep-disordered breathing has been identified. Anyone weighing device costs against what an insurer will and will not fund should read our practical step-by-step guide to nasal stent costs and insurance in Europe before deciding what to try first.

Frequently Asked Questions